TY - JOUR
T1 - Management of immunotherapy-related toxicities, version 1.2019
AU - Thompson, John A.
AU - Schneider, Bryan J.
AU - Brahmer, Julie
AU - Andrews, Stephanie
AU - Armand, Philippe
AU - Bhatia, Shailender
AU - Budde, Lihua E.
AU - Costa, Luciano
AU - Davies, Marianne
AU - Dunnington, David
AU - Ernstoff, Marc S.
AU - Frigault, Matthew
AU - Hoffner, Brianna
AU - Hoimes, Christopher J.
AU - Lacouture, Mario
AU - Locke, Frederick
AU - Lunning, Matthew
AU - Mohindra, Nisha A.
AU - Naidoo, Jarushka
AU - Olszanski, Anthony J.
AU - Oluwole, Olalekan
AU - Patel, Sandip P.
AU - Reddy, Sunil
AU - Ryder, Mabel
AU - Santomasso, Bianca
AU - Shofer, Scott
AU - Sosman, Jeffrey A.
AU - Wahidi, Momen
AU - Wang, Yinghong
AU - Johnson-Chilla, Alyse
AU - Scavone, Jillian L.
N1 - Publisher Copyright:
© 2019 Harborside Press. All Rights Reserved.
PY - 2019/3
Y1 - 2019/3
N2 - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.
AB - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.
UR - http://www.scopus.com/inward/record.url?scp=85062877270&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000461084700008&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2019.0013
DO - 10.6004/jnccn.2019.0013
M3 - Article
C2 - 30865922
SN - 1540-1405
VL - 17
SP - 255
EP - 289
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 3
ER -